Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,458 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matching Oral Placebo Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Free Fatty Acids and Vascular Function in Subjects With Diabetes

NCT00153179
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
acipimox, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 15, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

NCT03097861
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
67
States / cities
Birmingham, Alabama • Foley, Alabama • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 15, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Onset of Action of a Fast Release Aspirin

NCT01420094
View directory record Official record
Conditions
Healthy Subjects
Interventions
Acetylsalicyclic acid (Fast release Aspirin, BAY1019036), Acetaminophen (Tylenol extra strength), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years to 45 Years
Enrollment
510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 15, 2026, 4:18 PM EDT
Terminated Phase 2 Interventional

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

NCT01425970
View directory record Official record
Conditions
Hepatitis C
Interventions
INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anaheim, California • La Jolla, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 15, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

Randomized Trial of Adult Participants With Generalized Anxiety Disorder

NCT03829241
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Troriluzole, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
53
States / cities
Little Rock, Arkansas • Colton, California • Encino, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 15, 2026, 4:18 PM EDT
Not yet recruiting Phase 4 Interventional

Combination CurQD and Vedolizumab in Ulcerative Colitis

NCT07665294
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
CurQD, Placebo, Vedolizumab
Drug
Lead sponsor
Ryan C Ungaro
Other
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 4:18 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

NCT06619860
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
VX-993, Pregabalin, Placebo (matched to pregabalin), Placebo (matched to VX-993)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Cullman, Alabama • Bakersfield, California • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 15, 2026, 4:18 PM EDT
Completed Phase 2 Interventional

Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients

NCT00393120
View directory record Official record
Conditions
HIV Infections
Interventions
INCB009471, Placebo comparator
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Oct 15, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

NCT05296629
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
DFD-29, Doxycycline, Placebo
Drug
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
27
States / cities
Rogers, Arkansas • Cerritos, California • Fremont, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 15, 2026, 4:18 PM EDT
Completed Phase 4 Interventional

Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics

NCT03012529
View directory record Official record
Conditions
Osteomyelitis, Diabetes, Amputation
Interventions
Rifampin, Riboflavin Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
30
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 15, 2026, 4:18 PM EDT
Completed Phase 2 Interventional

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

NCT04693195
View directory record Official record
Conditions
Chronic Pruritus, Atopic Dermatitis
Interventions
BLU-5937, Placebo
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
28
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 15, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Results available

Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)

NCT05813275
View directory record Official record
Conditions
OSA
Interventions
AD109, Placebo
Drug
Lead sponsor
Apnimed
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
65
States / cities
Tuscaloosa, Alabama • Mesa, Arizona • Phoenix, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis

NCT00761657
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia
Interventions
Roxadustat, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
34
States / cities
Peoria, Arizona • Tempe, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 15, 2026, 4:18 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

NCT07007793
View directory record Official record
Conditions
Primary Hyperaldosteronism
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Farmington, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 15, 2026, 4:18 PM EDT
Completed Not applicable Interventional Results available

Effect of Exercise in OI

NCT00770484
View directory record Official record
Conditions
Orthostatic Intolerance, Postural Tachycardia Syndrome
Interventions
Propranolol then Placebo, Placebo then Propranolol
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Oct 15, 2026, 4:18 PM EDT
Recruiting Phase 2 Interventional

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

NCT06671054
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
AP1189, 40 mg, AP1189, 70 mg, AP1189, 100 mg, AP1189 matching placebo
Drug
Lead sponsor
SynAct Pharma Aps
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Cutler Bay, Florida • Miami, Florida • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 15, 2026, 4:18 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome

NCT07218653
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Indomethacin, Placebo, MRI
Drug · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 15, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects

NCT01530022
View directory record Official record
Conditions
Healthy
Interventions
Lacosamide (LCM), Carbamazepine Immediate Release (CBZ-IR)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 15, 2026, 4:18 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

NCT01568112
View directory record Official record
Conditions
Healthy
Interventions
BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
25 Years to 55 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 15, 2026, 4:18 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT04622293
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Interventions
Solriamfetol Oral Tablet [Sunosi], Placebo
Drug
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 15, 2026, 4:18 PM EDT
Recruiting Phase 2 Interventional

Sit Less, Interact and Move More (SLIMM) 2 Study

NCT05173714
View directory record Official record
Conditions
Chronic Kidney Diseases, Obesity
Interventions
SLIMM, Standard Resistance Training, Guided Resistance Training, Placebo, Semaglutide
Behavioral · Drug
Lead sponsor
Srinvasan Beddhu
Other
Eligibility
20 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Stanford, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 15, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

NCT01130272
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
288
States / cities
Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 225 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 15, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Results available

Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal

NCT03887429
View directory record Official record
Conditions
Impulse Control Disorders
Interventions
SXC-2023, Placebos
Drug
Lead sponsor
Promentis Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Lincoln, Nebraska • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 15, 2026, 4:18 PM EDT
Terminated Phase 3 Interventional

Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

NCT04684511
View directory record Official record
Conditions
Hemophilic Arthropathy
Interventions
TRM-201 (Rofecoxib), Placebo
Drug
Lead sponsor
Tremeau Pharmceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 15, 2026, 4:18 PM EDT